Detail akcie Genfit online

Business Summary: Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Genfit SA revenues increased 44% to EUR38.2M. Net loss applicable to common stockholders increased 22% to EUR28.9M. Revenues reflect Revenue increase of 41% to EUR28.6M, Operating Subsidies increase from EUR34K to EUR3.3M, Other Operating Income increase of 45% to EUR464K. Higher net loss reflects Foreign Exchange Gain decrease of 94% to EUR452K (income), R&D Subcontractors increase of 35% to EUR23.5M (expense).